Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: Similar hemofilter survival but significantly less bleeding

Journal of Nephrology

Volumn 20, Issue 5, 2007, Pages 602-608

  Betjes, Michiel G H ^a   van Oosterom, Daniella ^a   van Agteren, Madelon ^a   van de Wetering, Jaqueline ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulation; Bleeding; Citrate; Hemofiltration; Heparin

Indexed keywords

CALCIUM CHLORIDE; CITRATE TRISODIUM; HEMOGLOBIN; HEPARIN; HYPERTENSIVE AGENT; ANTICOAGULANT AGENT; CITRIC ACID;

ADULT; ANTICOAGULATION; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HYPERNATREMIA; HYPOCALCEMIA; HYPOTENSION; INCIDENCE; KIDNEY FAILURE; MALE; METABOLIC ALKALOSIS; METABOLIC DISORDER; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; SYSTEMIC THERAPY; THROMBOSIS; CHEMICALLY INDUCED DISORDER; CRITICAL ILLNESS; HEMOFILTRATION; KAPLAN MEIER METHOD; METHODOLOGY; MIDDLE AGED; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME; VEIN THROMBOSIS;

ANTICOAGULANTS; CITRATES; CRITICAL ILLNESS; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOFILTRATION; HEMORRHAGE; HEPARIN; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY FAILURE; MALE; METABOLIC DISEASES; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 38149140050     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Tan HK, Baldwin l, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. Intensive Care Med 2000; 26: 1652-7.
2. Van de Wetering J, Westendorp RG, van der Hoeven JG, Stolk B, Feuth JD, Chang PC. Heparin use in continuous renal replacement procedures: The struggle between filter coagulation and patient hemorrhage. J Am Soc Nephrol 1996; 7: 145-50.
3. Gabutti L, Marone C, Colucci G, Duchini F, Schonholzer C. Citrate anticoagulation in continuous venovenous hemodi-afiltration: A metabolic challenge. Intensive Care Med 2002;28: 1419-25.
4. Mehta RL, Letteri JM. Current status of renal replacement therapy for acute renal failure: A survey of US nephrologists. The National Kidney Foundation Council on Dialysis. Am J Nephrol 1999; 19: 377-82.
5. Hyman A, Mendelssohn DC. Current Canadian approaches to dialysis for acute renal failure in the ICU. Am J Nephrol 2002; 22: 29-34.
6. Monchi M, Berghmans D, Ledoux D, Canivet JL, Dubois B, Dumas P. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: A prospective randomized study. Intensive Care Med 2004; 30: 260-5.
7. Kutsogiannis DJ, Gibney RT, Stollery D, Gao J. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. Kidney Int 2005; 67: 2361-7.
8. Oudemans-van Straaten HM, Wester JP, de Pont AC, Schetz MR. Anticoagulation strategies in continuous renal replacement therapy: Can the choice be evidence based. Intensive Care Med 2006; 32: 188-202.
9. Le Gall JR, Lemeshow S, Saulnier F. A new simplified acute physiology score (SAPII) based on a European/North American multicenter study. JAMA 1993; 270: 2957-63.
10. Mehta RL, McDonald BR, Aguilar MM, Ward DM. Regional citrate anticoagulation for continuous arterio-venous haemodialysis in critically ill patients. Kidney Int 1990; 38: 976-81.
11. Cointault O, Kamar N, Bodes P, Lavayssiere L, Angles O, Rostaing L, Genestal M, Durand D. Regional citrate anticoagulation in continuous venovenous haemodiafiltration using commercial solutions. Nephrol Dial Transplant 2004; 19: 171-8.
12. Morgera S, Haase M, Rückert M, Krieg H, Kastrup M, Krausch D, Vargas-Hein O, Zuckermann-Becker H, Peters H, Pohlmeier R, Neumayer HH. Regional citrate anticoagulation in continuous hemodialysis: Acid-base and electrolyte balance at an increased dose of dialysis. Nephron Clin Pract 2005; 101: c211-9.
13. Bihorac A, Ross EA. Continuous venoveneus hemofiltration with citrate-based replacement fluid: Efficaty, safety, and impact on nutrition. Am J Kidney Dis 2005; 46: 908-18.
14. Hetzel GR, Taskaya G, Sucker C, Hennersdorf M, Grabensee B, Schmitz M. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. Am J Kidney Dis 2006; 48: 806-11.
15. Cutts MW, Thomas AN, Kisher R. Transfusion requirements during veno-venous haemofiltration: The importance of filter life. Intensive Care Med 2000; 26: 1694-7.
16. Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R. Continuous is not continuous: The incidence and impact of circuit "down rime" on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 2003; 29: 575-8.